Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $991,929.36 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $21.96 on Monday. The business’s 50-day simple moving average is $22.28 and its 200 day simple moving average is $21.52. The company has a market cap of $2.67 billion, a P/E ratio of 18.61, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.50.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the period. Larson Financial Group LLC raised its stake in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $65,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.